Literature DB >> 11772393

Novel alternative splice variants of rat phosphodiesterase 7B showing unique tissue-specific expression and phosphorylation.

Takashi Sasaki1, Jun Kotera, Kenji Omori.   

Abstract

cDNA species coding for novel variants of cyclic-AMP-specific phosphodiesterases (PDEs), namely the PDE7B family, were isolated from rats and characterized. Rat PDE7B1 (RNPDE7B1) was composed of 446 amino acid residues. Rat PDE7B2 (RNPDE7B2) and PDE7B3 (RNPDE7B3), which possessed unique N-terminal sequences, consisted of 359 and 459 residues respectively. Northern hybridization analysis showed that rat PDE7B transcripts were particularly abundant in the striatum and testis. PCR analyses revealed that rat PDE7B2 transcripts were restricted to the testis and that low levels of PDE7B3 transcripts were expressed in the heart, lung and skeletal muscle. In situ hybridization analysis demonstrated that rat PDE7B transcripts were expressed in striatal neurons and spermatocytes. In spermatocytes, rat PDE7B transcripts were expressed in a stage-specific manner during spermatogenesis. The K(m) values of recombinant rat PDE7B1, PDE7B2 and PDE7B3 for cAMP were 0.05, 0.07 and 0.05 microM respectively. Each rat PDE7B variant was the most sensitive to 3-isobutyl-1-methylxanthine (IC(50) 1.5-2.1 microM). Two phosphorylation sites for cAMP-dependent protein kinase (PKA) were found in rat PDE7B1 and PDE7B3, whereas rat PDE7B2 possessed one site. PKA-dependent phosphorylation was observed in C-terminal phosphorylation sites of three rat PDE7B variants, in addition to unique N-terminal regions of rat PDE7B1 and PDE7B3. Unique tissue distribution and PKA-dependent phosphorylation of PDE7B variants suggested that each variant has a specific role for cellular functions via cAMP signalling in various tissues.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11772393      PMCID: PMC1222301          DOI: 10.1042/0264-6021:3610211

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  43 in total

1.  Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase.

Authors:  S H Soderling; S J Bayuga; J A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

2.  Stimulation of p70S6 kinase via a growth hormone-controlled phosphatidylinositol 3-kinase pathway leads to the activation of a PDE4A cyclic AMP-specific phosphodiesterase in 3T3-F442A preadipocytes.

Authors:  S J MacKenzie; S J Yarwood; A H Peden; G B Bolger; R G Vernon; M D Houslay
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

3.  Phosphorylation of the gamma subunit of the retinal photoreceptor cGMP phosphodiesterase by the cAMP-dependent protein kinase and its effect on the gamma subunit interaction with other proteins.

Authors:  L X Xu; Y Tanaka; V A Bonderenko; I Matsuura; H Matsumoto; A Yamazaki; F Hayashi
Journal:  Biochemistry       Date:  1998-04-28       Impact factor: 3.162

Review 4.  Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3).

Authors:  E Degerman; P Belfrage; V C Manganiello
Journal:  J Biol Chem       Date:  1997-03-14       Impact factor: 5.157

5.  Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene.

Authors:  J H Cha; C M Kosinski; J A Kerner; S A Alsdorf; L Mangiarini; S W Davies; J B Penney; G P Bates; A B Young
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

6.  Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart.

Authors:  P Han; X Zhu; T Michaeli
Journal:  J Biol Chem       Date:  1997-06-27       Impact factor: 5.157

7.  Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B.

Authors:  A Z Zhao; H Zhao; J Teague; W Fujimoto; J A Beavo
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

8.  Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation.

Authors:  C Sette; M Conti
Journal:  J Biol Chem       Date:  1996-07-12       Impact factor: 5.157

Review 9.  Transcription factors responsive to cAMP.

Authors:  P Sassone-Corsi
Journal:  Annu Rev Cell Dev Biol       Date:  1995       Impact factor: 13.827

10.  cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model.

Authors:  R Hoffmann; I R Wilkinson; J F McCallum; P Engels; M D Houslay
Journal:  Biochem J       Date:  1998-07-01       Impact factor: 3.857

View more
  10 in total

Review 1.  Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson's Disease?

Authors:  Dominic Ngima Nthenge-Ngumbau; Kochupurackal P Mohanakumar
Journal:  Mol Neurobiol       Date:  2017-01-06       Impact factor: 5.590

Review 2.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

Review 3.  The role of phosphodiesterases in schizophrenia : therapeutic implications.

Authors:  Judith A Siuciak
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

4.  Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice.

Authors:  Miriam Redondo; Valle Palomo; José Brea; Daniel I Pérez; Rocío Martín-Álvarez; Concepción Pérez; Nuria Paúl-Fernández; Santiago Conde; María Isabel Cadavid; María Isabel Loza; Guadalupe Mengod; Ana Martínez; Carmen Gil; Nuria E Campillo
Journal:  ACS Chem Neurosci       Date:  2012-08-08       Impact factor: 4.418

5.  Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL.

Authors:  Sang-Woo Kim; Deepak Rai; Morgan R McKeller; Ricardo C T Aguiar
Journal:  Blood       Date:  2009-04-15       Impact factor: 22.113

6.  Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease.

Authors:  Jose A Morales-Garcia; Miriam Redondo; Sandra Alonso-Gil; Carmen Gil; Concepción Perez; Ana Martinez; Angel Santos; Ana Perez-Castillo
Journal:  PLoS One       Date:  2011-02-24       Impact factor: 3.240

7.  Specific use of start codons and cellular localization of splice variants of human phosphodiesterase 9A gene.

Authors:  Carles Rentero; Pere Puigdomènech
Journal:  BMC Mol Biol       Date:  2006-11-08       Impact factor: 2.946

Review 8.  Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

Authors:  Olga A H Reneerkens; Kris Rutten; Harry W M Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

9.  Inhibiting PDE7A Enhances the Protective Effects of Neural Stem Cells on Neurodegeneration and Memory Deficits in Sevoflurane-Exposed Mice.

Authors:  Yanfang Huang; Yingle Chen; Zhenming Kang; Shunyuan Li
Journal:  eNeuro       Date:  2021-07-07

Review 10.  Role of Phosphodiesterase 7 (PDE7) in T Cell Activity. Effects of Selective PDE7 Inhibitors and Dual PDE4/7 Inhibitors on T Cell Functions.

Authors:  Marianna Szczypka
Journal:  Int J Mol Sci       Date:  2020-08-25       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.